Nvidia invests $50 million in AI drug discovery company Recursion Pharmaceuticals

Nvidia invested $50 million in biotech company Recursion Pharmaceuticals to advance AI for drug discovery.
Recursion will use its data and Nvidia's cloud platform to train advanced AI models for identifying potential new therapies.
The partnership reflects the growing potential of AI in the pharmaceutical industry.
Recursion's stock price jumped over 80% after the announcement of Nvidia's investment.
Recursion partners with drugmakers like Bayer and Roche to develop new drugs using its AI technology.